Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors

Neuropsychopharmacology

Volumn 41, Issue 9, 2016, Pages 2344-2351

  Falcon, Edgardo ^a   Browne, Caroline A ^a   Leon, Rosa M ^a   Fleites, Vanessa C ^a   Sweeney, Rachel ^a   Kirby, Lynn G ^b   Lucki, Irwin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DESIPRAMINE; KAPPA OPIATE RECEPTOR; MESSENGER RNA; NORBINALTORPHIMINE; PROTEIN DERIVATIVE; PROTEIN OPRK1; PROTEIN OPRM1; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; DELTA OPIATE RECEPTOR; MU OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; DRUG EFFECT; FORCED SWIM TEST; IMMOBILITY; LIGHT-DARK TEST; LIMBIC CORTEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUCROSE PREFERENCE TEST; ANIMAL; ANIMAL BEHAVIOR; BRAIN; C57BL MOUSE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; MENTAL STRESS; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; BUPRENORPHINE; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRESS, PSYCHOLOGICAL;

EID: 84964317971     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.38     Document Type: Article

References (34)

1. Almatroudi A, Husbands SM, Bailey CP, Bailey SJ (2015). Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. J Psychopharmacol 29: 812-821.
2. Balu DT, Hodes GE, Anderson BT, Lucki I (2009). Enhanced sensitivity of the MRL/MpJ mouse to the neuroplastic and behavioral effects of chronic antidepressant treatments. Neuropsychopharmacology 34: 1764-1773.
3. Bodkin JA, Zornberg GL, Lukas SE, Cole JO (1995). Buprenorphine treatment of refractory depression. Clin Psychopharmacology 15: 49-57.
4. Browne CA, van Nest DS, Lucki I (2015). Antidepressant-like effects of buprenorphine in rats are strain dependent. Behav Brain Res 278C: 385-392.
5. Carlezon Jr. W.A., Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS et al (2006). Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316: 440-447.
6. Carr GV, Bangasser DA, Bethea T, Young M, Valentino RJ, Lucki I (2010). Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacology 35: 752-763.
7. Cowan A (2007). Buprenorphine: the basic pharmacology revisited. J Addict Med 1: 68-72.
8. Delaney G, Dawe KL, Hogan R, Hunjan T, Roper J, Hazell G et al (2012). Role of nociceptin/orphanin FQ and NOP receptors in the response to acute and repeated restraint stress in rats. J Neuroendocrinol 24: 1527-1541.
9. Ehrich E, Turncliff R, Du Y, Leigh-Pemberton R, Fernandez E, Jones R et al (2015). Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology 40: 1448-1455.
10. Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I (2015). Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology 232: 907-915.
11. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F et al (2000). Mice deficient for delta-And mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25: 195-200.
12. Hurd YL, Herman MM, Hyde TM, Bigelow LB, Weinberger DR, Kleinman JE (1997). Prodynorphin mRNA expression is increased in the patch vs matrix compartment of the caudate nucleus in suicide subjects. Mol Psychiatry 2: 495-500.
13. Ipser JC, Terburg D, Syal S, Phillips N, Solms M, Panksepp J et al (2013). Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology 38: 166-170.
14. Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM et al (2014). Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry 75: e785-e793.
15. Kennedy SE, Koeppe RA, Young EA, Zubieta JK (2006). Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63: 1199-1208.
16. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C (2008). The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neuroscience 28: 407-414.
17. Liberzon I, Zubieta JK, Fig LM, Phan KL, Koeppe RA, Taylor SF (2002). mu-Opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci USA 99: 7084-7089.
18. Lucki I, Dalvi A, Mayorga AJ (2001). Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155: 315-322.
19. Lutfy K, Cowan A (2004). Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2: 395-402.
20. Lutz PE, Kieffer BL (2013). Opioid receptors: distinct roles in mood disorders. Trends Neurosci 36: 195-206.
21. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens Jr. W.C. et al (2003). Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305: 323-330.
22. McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stressinduced behavioral responses. J Neuroscience 23: 5674-5683.
23. Mozhui K, Karlsson RM, Kash TL, Ihne J, Norcross M, Patel S et al (2010). Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability. J Neuroscience 30: 5357-5367.
24. Nyhuis PW, Gastpar M, Scherbaum N (2008). Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacology 28: 593-595.
25. Pietrzak RH, Naganawa M, Huang Y, Corsi-Travali S, Zheng MQ, Stein MB et al (2014). Association of in vivo kappa-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology. JAMA Psychiatry 71: 1262-1270.
26. Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336.
27. Schmidt HD, Duman RS (2010). Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 35: 2378-2391.
28. Strekalova T, Steinbusch HW (2010). Measuring behavior in mice with chronic stress depression paradigm. Prog Neuropsychopharmacol Biol Psychiatry 34: 348-361.
29. Syal S, Ipser J, Terburg D, Solms M, Panksepp J, Malcolm-Smith S et al (2015). Improved memory for reward cues following acute buprenorphine administration in humans. Psychoneuroendocrinology 53: 10-15.
30. Willner P (1997). Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 134: 319-329.
31. Willner P (2005). Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52: 90-110.
32. Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y et al (2014). The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther 141: 283-299.
33. Yamada H, Nakamoto H, Suzuki Y, Ito T, Aisaka K (2002). Pharmacological profiles of a novel opioid receptor-like1 (ORL (1)) receptor antagonist, JTC-801. Br J Pharmacol 135: 323-332.
34. Zhang Y, Simpson-Durand CD, Standifer KM (2015). Nociceptin/ orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-Traumatic stress disorder. Br J Pharmacol 172: 571-582.